Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Medtronic
Express Scripts
Harvard Business School
Mallinckrodt

Last Updated: August 19, 2022

Investigational Drug Information for Fluzoparib


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Fluzoparib?

Fluzoparib is an investigational drug.

There have been 39 clinical trials for Fluzoparib. The most recent clinical trial was a Phase 1 trial, which was initiated on August 19th 2020.

The most common disease conditions in clinical trials are Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, and Lung Neoplasms. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Tianjin Medical University Second Hospital, and Tianjin Medical University Cancer Institute and Hospital.

There are two US patents protecting this investigational drug and twenty-one international patents.

Recent Clinical Trials for Fluzoparib
TitleSponsorPhase
Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance TreatmentXiaohua Wu MDPhase 2
A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing CancersSuzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 2
A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian CancerThe Second Affiliated Hospital of Shandong First Medical UniversityPhase 2

See all Fluzoparib clinical trials

Clinical Trial Summary for Fluzoparib

Top disease conditions for Fluzoparib
Top clinical trial sponsors for Fluzoparib

See all Fluzoparib clinical trials

US Patents for Fluzoparib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Fluzoparib See Plans and Pricing Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof Jiangsu Hansoh Pharmaceutical Co., Ltd. (Lianyungang, Jiangsu, CN) See Plans and Pricing
Fluzoparib See Plans and Pricing Methods of using phthalazinone ketone derivatives Jiangsu Hansoh Pharmaceutical Co., Ltd. (Lianyungang, Jiangsu, CN) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Fluzoparib

Drugname Country Document Number Estimated Expiration Related US Patent
Fluzoparib Australia AU2011288876 2030-08-09 See Plans and Pricing
Fluzoparib Brazil BR112013002220 2030-08-09 See Plans and Pricing
Fluzoparib Canada CA2806324 2030-08-09 See Plans and Pricing
Fluzoparib China CN102372716 2030-08-09 See Plans and Pricing
Fluzoparib China CN102686591 2030-08-09 See Plans and Pricing
Fluzoparib European Patent Office EP2604610 2030-08-09 See Plans and Pricing
Fluzoparib Spain ES2582315 2030-08-09 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Medtronic
Express Scripts
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.